Related Experiment Video
Updated: Jun 19, 2026

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice
Published on: December 8, 2023
[Mobilisation of haematopoietic stem cells with plerixafor--secondary publication]
Per Boye Hansen1, Eva Gaarsdal
1Medicinsk Haematologisk Afdeling L, Herlev Hospital, DK-2730 Herlev, Denmark. peboha@heh.regionh.dk
Plerixafor (AMD3100) is a selective antagonist of a receptor expressed on haematopoietic stem cells. This receptor normally binds to a ligand on bone marrow stromal cells, responsible for the homing and keeping the stem cells in place. Plerixafor has been successfully used in clinical trails in patients with malignant lymphoma and multiple myeloma, where mobilization of stem cells with granulocyte colony-stimulating factor for leukapheresis and later stem cell transplantation were not possible. Plerixafor has also been given with success to healthy donors for harvest and haematopoietic allograft.
Plerixafor (AMD3100) is a selective antagonist of a receptor expressed on haematopoietic stem cells. This receptor normally binds to a ligand on bone marrow stromal cells, responsible for the homing and keeping the stem cells in place. Plerixafor has been successfully used in clinical trails in patients with malignant lymphoma and multiple myeloma, where mobilization of stem cells with granulocyte colony-stimulating factor for leukapheresis and later stem cell transplantation were not possible. Plerixafor has also been given with success to healthy donors for harvest and haematopoietic allograft.
Related Concept Videos
Hematopoiesis
Multipotency of Hematopoietic Stem Cells
Regulation of Hematopoietic Stem Cells

